

Parkinson's disease guideline committee meeting

Date: 19/10/2015

Location: Bollin, NICE Offices Manchester, Piccadilly Plaza, M1 4BT

Minutes: Final

| Committee members present: | | | |
|----------------------------|---------------------------|--|--|
| Paul Cooper (Chair) | Present for all | | |
| Richard Grunewald (RG) | Present for all | | |
| Alistair Church (AC) | Present for all | | |
| Fiona Lindop (FL) | Present for all | | |
| Paul Shotbolt (PS) | Present for all | | |
| Ivan Benett (IB) | Present for items 1 and 2 | | |
| Jane Little (JL) | Present for all | | |
| Janine Barnes (JB) | Present for all | | |
| Matthew Sullivan (MS) | Present for all | | |
| Debbie Davies (DD) | Present for all | | |
| Richard Walker (RW) | Present for all | | |
| Robin Fackrell (RF) | Present for all | | |

| In attendance: | | |
|------------------------|---|-------------------------------------|
| Gabriel Rogers (GR) | Technical Adviser – Health Economics | Present for all |
| Steven Ward (SW) | Health Economist | Present for all |
| Sue Spiers (SS) | Associate Director | Present for all |
| Louise Shires (LS) | Commissioning Manager | Present for all |
| Sarah Stephenson (SSt) | Commissioning Manager | Present for all items except item 3 |

| Observers: | |
|------------|------------------|
| Aimely Lee | External visitor |

| Committee member apologies: | | |
|-----------------------------|------------------|--|
| Graham Lennox | Committee member | |
| Lynne Osbourne | Committee member | |

1. Welcome, introductions, minutes, Dol and matters arising

The Chair welcomed the Committee members and attendees to the eighth meeting on Parkinson's disease.

The Chair asked those present to declare any conflicts of interest relevant to the areas being discussed or potential new conflicts.

| Name | Declaration | Classification | Chairs action |
|------------------------|---|---|-------------------------|
| Robin Fackrell (RF) | Chairing meeting for UCB in December. No honorarium will be received | Personal non- financial, non- specific interest | Declare and participate |
| | 2. Chair of Future Leaders in Movement Disorders in December 2015. No honorarium will be received | Personal, non- financial, specific interest | Declare and participate |
| | 3. Speaker at Positive Steps in February 2016. No honorarium will be received. | Personal, non- financial, specific interest | Declare and participate |
| | 4. Speaker at UCB | Personal, non- | Declare and |

| | sponsored talk re Pain in Parkinson's disease. No honorarium will be received. | financial, specific interest | participate |
|---------------------------|--|--|--------------------------|
| Richard Walker (RW) | 1. Speaker at British Geriatric Bladder and Bowel Society in November 2015. No expenses will be received. | Non-specific, non-financial interest | Declare and participate. |
| Fiona Lindop (FL) | Attendance at UCB sponsored meeting. No expenses will be received. | Personal non- financial, specific, interest | Declare and participate |
| Paul Cooper (PC) | 1. Presenting at American Epilepsy Society meeting. Medtronic providing statistical support for data analysis but no financial incentive | Non-specific, non- personal financial interest | Declare and participate |
| Richard Grunewald (RG) | 1. Presentation of UCB funded lecture on clozapine for East Midlands Parkinsons Excellence network (honorarium donated to Parkinsons UK) | Specific, personal non-financial | Declare and participate |

an accurate record of the discussions.

LS provided an update on progress with Duodopa and NHS England in terms of their commissioning policy.

2. RQ11 - Effectiveness of pharmacological interventions for the treatment of orthostatic hypotension in PD

SW presented the evidence found relating to this review question. The results were presented in relation to the following outcomes – adverse events and mortality; falls, non-motor features; blood pressure; autonomic dysfunction. No evidence was found in relation to health related quality of life and carer burden. The Committee debated the quality of the evidence and considered their experiences of the effectiveness of pharmacological interventions. The group went on to make recommendations.

3. RQ12 – Effectiveness of pharmacological interventions to treat thermoregulatory dysfunction in PD

SW informed the committee that no evidence had been found for this review question. The committee felt unable to make any significant new recommendations for this question.

4. Review Protocols

SW and GR presented the draft review protocol for

RQ20 – What is the comparative effectiveness of donepezil, galantamine, memantine and rivastigmine for cognitive enhancement in dementia associated with PD? The committee discussed and agreed the range of interventions for inclusion within the protocol.

Additional Agenda Item - Health Economics

Due to the previous agenda items progressing well an additional agenda item was included which discussed further the development of the proposed health economic model.

5. Linking evidence to recommendations (LETR) tables

The Committee reviewed the draft summary of their earlier discussions about how the draft recommendations were formulated (LETR tables).

These were agreed as an accurate record. It was confirmed the tables would be written up in full prose and sent out to the committee in the week following the meeting.

6. Summary and next steps

The Chair thanked the group for their attendance and contributions.

SS confirmed the dates of the next meeting, advised that the LETR tables and chapters will be circulated for information and confirmed the date and location of the next meeting.

Date of next meeting: 21 January 2016

Location of next meeting: NICE Offices, Manchester